RUNX1 and acute myeloid leukemia: As a result, GO was re-approved by the FDA in 2017 and the EMA in 2018 for the first-line treatment of CD33-expressing AML [2], leading to its incorporation into standard induction regimens, particularly for patients with CBF-AML harboring the t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB::MYH11 fusion genes [6–8].